PacBio will host a workshop titled “Accurate and Affordable Long-Read Sequencing of Human Genomes on the Sequel® II System,” which will take place on
Shawn Levy, PhD, Faculty Investigator, Genomic Services Laboratory, HudsonAlpha Institute for Biotechnology, who will share information about the Institute’s adoption of PacBio human whole-genome sequencing for multiple on-going human genetics projects – including the NIH-funded Clinical Sequencing Exploratory Research (CSER) project. Naomichi Matsumoto, MD, PhD, Chair of Human Genetics at Yokohama City University, who will discuss the use of PacBio long-read sequencing for disease genome analysis. Emily Hatas, Senior Director of Business Development at PacBio, who will present information about the latest advancements in SMRT Sequencing for human genetics research, including the new Sequel II Consumables 2.0 and SMRT Link v8.0 release, and ways users can now detect structural variants for up to two ~3Gb genomes, or characterize alternative splicing across a whole transcriptome, with just one SMRT Cell 8M.
Interested attendees can pre-register for the workshop.
“We are looking forward to sharing our latest product updates and scientific advances with the human genetics community, which will allow them to sequence human genomes and transcriptomes with confidence,” said Dr. Korlach. “Through our workshop and other presentations, attendees will be able to see the power of SMRT Sequencing for de novo genome assembly, targeted sequencing, isoform sequencing and variant detection, including finding important structural variants.”
The following podium and poster presentations represent a selection of the more than 50 presentations that will include SMRT Sequencing data, which represents a doubling over the number last year.
- #57 on Wednesday, 10/16 at
5:30 p.m.: “Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells,” by Hagen Tilgner, PhD, from Weill Cornell Medicine.
- #221 on Thursday, 10/17 at
4:15 p.m.: “A robust and production-level approach to haplotype-resolved assembly of single individuals,” presented by Shilpa Garg, PhDfrom Harvard Medical School.
- #223 on Thursday, 10/17 at
4:15 p.m.: “Long-read single molecule, real-time ( SMRT) sequencing of NUDT15: Phased full gene haplotyping and pharmacogenomic allele discovery,” with Yao Yang, PhD, from the Icahn School of Medicineat Mount Sinai.
- #313 on Saturday, 10/19 at
9 a.m.: “Incorporating long transcriptomic data into GENCODE,” with Jane Loveland, PhD, from European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, United Kingdom.
- Poster #1068: “Comprehensive structural and copy-number variant detection with long reads,” by Aaron Wenger, PhD, of PacBio.
- Poster #1455: “Full-length RNA-seq of Alzheimer brain sample on the PacBio Sequel II platform,” by Elizabeth Tseng, PhD, of PacBio.
- Poster #1692: “High-quality human genomes achieved through HiFi sequence data and
FALCON-Unzip Assembly,” by Zev Kronenberg, PhD, of PacBio.
- Poster #1866: “Detection and phasing of small variants in Genome in a Bottle samples with highly accurate long reads,” by William Rowell of PacBio.
Other scientific program highlights featuring SMRT Sequencing include the CoLab Session on Friday, October 18 at 10:00 a.m. in Theater 3, where ASHG meeting attendees will have the opportunity to hear from PacBio scientists on the exhibit hall floor in the session “PacBio Sequel II System: Structural Variants and Whole Transcriptome in 1 SMRT Cell Each.” The session will include talks on whole genome sequencing for structural variation discovery and Iso-Seq® Analysis. Attendees can also visit PacBio at booth #1020.
PacBio will be sponsoring a grant program for scientists interested in a chance to win free SMRT Sequencing for their human genetics sequencing projects, including scientists who are not attending this year’s ASHG annual meeting. For more information visit www.pacb.com/smrtgrant.
About Pacific Biosciences
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to product updates or enhancements, upcoming conference presentations, the attributes of the Sequel II System, the future availability, uses, accuracy, quality or performance of, or benefits of using, products or technologies, the suitability or utility of methods, products or technologies for particular applications, studies or projects, the importance of long-read sequencing data, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Source: Pacific Biosciences of California, Inc.